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Abstract Advanced glycation endproducts (AGEs), which
accumulate on long-lived proteins and protein deposits (amy-
loids), induce the expression of proinflammatory cytokines
through NF-UB-dependent pathways. Hyaluronic acid with a
molecular weight above 1.2 MDa (HMW-HA) inhibits the AGE-
induced activation of the transcription factor NF-UB and the NF-
UB-regulated cytokines interleukin-1K, interleukin-6 and tumor
necrosis factor-K. Since the molecular weight of hyaluronic acid
in humans decreases with age and under conditions of oxidative
stress, it is likely that the protective effect of HMW-HA against
AGE-induced cellular activation is lost at sites of chronic
inflammation and in older age.
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1. Introduction
Advanced glycation endproducts (AGEs) are sugar- or sug-
ar degradation product-derived protein modi¢cations which
irreversibly crosslink long-lived proteins and thus contribute
to the formation of insoluble protein deposits. AGE forma-
tion begins with the reaction of nucleophilic protein side
chains, i.e. of lysine and arginine, with reducing sugars or
sugar-derived carbonyl and dicarbonyl compounds. This mod-
i¢cation, termed non-enzymatic glycosylation, glycation or
Maillard reaction, leads, through subsequent rearrangements,
dehydrations and oxidations, to the formation of a heteroge-
neous group of mostly £uorescent and brown products, the
so-called advanced glycation endproducts [1,2] (Fig. 1).
AGE-modi¢ed proteins elicit an acute-phase response in
phagocytotic cells, including microglia and macrophages,
and lead to the subsequent generation of free radicals like
superoxide and NO and the upregulation of pro-in£ammatory
cytokines, such as interleukin (IL) 1K, IL-6 and tumor ne-
crosis factor-K (TNF-K) [3,4]. AGEs exert their cellular e¡ects
by interacting with speci¢c cell surface receptors, the best
characterized of which is the receptor for AGEs (RAGE)[5].
AGEs have been shown to activate two major signal trans-
duction pathways: a redox-sensitive pathway involving
NADPH oxidase and the transcription factor NF-UB [6,7]
and a mitogenic pathway involving the small G-protein Ras,
protein kinases further downstream including ERK-2 and the
transcription factor AP-1 [8^10]. These two pathways con-
verge at the transcriptional level to induce the expression of
speci¢c pro-in£ammatory cytokines [5,11,12].
AGEs have been suggested to be inducers of chronic in£am-
mation and acute-phase responses in a variety of diseases. In
the brain of Alzheimer disease patients activated microglia are
found in close colocalization with AGE-modi¢ed L-amyloid
plaques [13^17].
Pharmacological interference with AGE-induced signal
transduction is considered to be a promising treatment strat-
egy for these in£ammatory conditions. A key second messen-
ger in AGE-activated signal transduction is the superoxide
anion and hydrogen peroxide which can be scavenged by in-
tracellularly acting antioxidants including 17-estradiol or thi-
octic acid [7,18]. However, as yet no physiological antagonist or
inhibitor of AGE-induced cell activation has been described.
Two observations suggested that hyaluronic acid (HA), a gly-
cosaminoglycan polymer of the extracellular matrix consisting
of repeat units of disaccharide, N-acetyl-D-glucosamine and
N-acetyl-D-glucuronic acid, might serve this purpose. For ex-
ample, HA-positive neurons have been shown to be less prone
to cell death in Alzheimer’s disease brain, suggesting that
these neurons are more resistant to the pathological processes
of AD, particularly to oxidative stress [19]. Secondly, applica-
tion of synthetic HA preparations is bene¢cial in chronic in-
£ammatory conditions associated with rheumatoid arthritis
and osteoarthritis. For example, injection of HA reduces total
amounts of leukotrienes, prostaglandins and IL-1K in synovial
£uid of the knee and the temporomandibular joint [20,21]. In
contrast, some groups show that a pro-in£ammatory response
can be induced by HA, i.e. an increase in IL-1, TNF-K, and
IL-8 [22] or an increase in the expression of ICAM-1 and
VCAM-1 [23]. However, a growing body of evidence suggests
that the chemical properties of HA, such as its molecular
weight, determine its pro- or anti-in£ammatory potential.
We describe high molecular weight HA (HMW-HA) acting
extracellularly to inhibit BSA-AGE-induced cell activation in
macrophages via NF-UB and, further downstream, IL-1K, IL-
6 and TNF-K. Since the molecular weight of HA decreases
with age and in regions of high radical load, we suggest that
HA may lose its protective properties under these conditions,
allowing a vicious circle of chronic in£ammation, oxidative
stress and radical-induced HA depolymerization.
2. Materials and methods
2.1. Materials
HA (MW: 1.2 MDa, 0.72 MDa and 0.6 MDa) LMW-HA (MW:
0.2^0.5 MDa) were purchased from Lifecore and Sigma, respectively.
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D-Glucuronic-acid, N-acetylglucosamine and chondroitin sulfate were
from Sigma, the anti-p50 antibody was supplied by Santa Cruz Bio-
technology. Cell culture reagents were from Gibco, PCR primer pairs
speci¢c for murine L-actin, TNF-K, IL-6 and IL-1K from Eurogentec.
2.2. Activation of murine macrophages
J774 (ATCC TIB 67) mouse macrophages were grown in 75 cm2
tissue culture £asks for 24^36 h until con£uence in RPMI 1640, 10%
FCS, supplemented with penicillin/streptomycin (100 U/ml, 100 Wg/
ml) and L-glutamine (2 mM) at 37‡C in 5% CO2. Macrophage acti-
vation was induced by the addition of 2 WM BSA-AGE. The negative
control contained 2 WM BSA and/or medium only. HA was added at
a concentration of 4 mg/ml 15 min before the start of the experiment.
The monoclonal anti-CD44 antibody was used at a concentration of
0.48 Wg/ml and added 15 min before addition of HA.
2.3. Production of AGEs
BSA-AGEs were produced by incubation of 1 mM BSA with 1 M
glucose in PBS, pH 7.4 at 50‡C for 6 weeks and the 2w-BSA-AGE
under the same conditions for 2 weeks. Since a steady and almost
linear increase in both £uorescence (370 nm excitation/440 nm emis-
sion) and absorbance at 400 nm was observed after 6 weeks and the
increase thereafter was marginal, the BSA was assumed to be max-
imally modi¢ed by AGEs. Unbound sugars were removed by exten-
sive dialysis with distilled water. Model AGEs were lyophilized and
resuspended in PBS (pH 7.4). Protein content was determined by the
Bradford assay, using BSA as a standard. AGE content was estimated
by measuring the optical density at 400 nm and the £uorescence at
440 nm. Although bacterial growth should be negligible under these
conditions, LPS content of the BSA-AGE preparation was further
minimized by passing it over a polymyxin column (Pierce). These
BSA-AGE preparations contained no endotoxin as judged by a neg-
ative result in the Limulus amebocyte lysate (LAL) assay (Bio-Whit-
taker, Inc.).
2.4. Preparation of nuclear protein extracts
Nuclear protein extracts (for determination of nuclear NF-UB by
electrophoretic mobility shift assay) were prepared essentially as de-
scribed by Hauf et al. [24]. Brie£y, PBS-washed macrophages were
scraped from the culture plate and collected by centrifugation. Pellets
were resuspended in 0.4 ml of hypotonic lysis bu¡er containing 10
mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT and 0.5 mM phenylmethylsulfonyl £uoride (PMSF). After
15 min on ice, Nonidet P40 was added to a ¢nal concentration of
0.5%. The cells were mixed for 10 s and then centrifuged for 30 s at
12 000Ug (4‡C). The pellets, containing the nuclei, were resuspended
in 140 Wl bu¡er containing 20 mM HEPES (pH 7.9), 0.4 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM DTT and 1 mM PMSF and
mixed for 30 min at 4‡C. After centrifugation (5 min, 4‡C,
12 000Ug), the supernatant ( = nuclear extract) was stored at 380‡C.
2.5. Electrophoretic mobility shift assay (EMSA)
The oligonucleotides representing the consensus sequence for NF-
UB (5P-AGC TTC AGA GGG GAC TTT CCG AGA GG-3P and 5P-
TCG ACC TCT CGG AAA GTC CCC TCT GA-3P) were hybridized
to form a double-stranded probe; and the ends were 32P-labeled with
Klenow polymerase. The binding reactions were performed on ice in a
volume of 15 Wl, containing 5 Wl 3Ubinding bu¡er (60 mM HEPES
(pH 7.9), 1 mM DTT, 3 mM EDTA, 150 mM KCl and 12% Ficoll),
20 000 cpm of 32P-labeled DNA probe, 7 Wg nuclear proteins, and 2 Wg
poly dIdC (Boehringer-Mannheim). After 30 min on ice, the com-
plexes were separated on a native 5% polyacrylamide gel and scanned.
For the supershift assays, the anti-p50 antibody was included at a
concentration of 1 mg/ml in the EMSA standard reaction mixture
20 min before the addition of the labeled oligonucleotides.
2.6. RT-PCR for detection of IL-6 and TNF-K expression
Cells were grown in cultured medium in 75cm2 tissue culture £asks
(1U106 cells per £ask) and incubated with BSA (2WM) or BSA-AGEs
(2WM) for 24h, then lysed with guanidinium thiocyanate. Total RNA
was prepared by phenol-extraction and reverse transcribed with Mo-
loney murine virus reverse transcriptase (20U/Wl). The primers used
for cytokine-speci¢c PCR have been described recently [25]. PCR was
performed with an initial denaturation step of 3min at 91‡C; then 30
cycles were performed as follows: 1min of denaturation at 91‡C, 1min
of annealing at 60‡C and 1min extension at 72‡C. The reaction prod-
ucts, IL-1K (308bp), IL-6 (154bp), L-actin (348bp) and TNF-K
(307bp) were visualized by electrophoresis of 15Wl of the reaction
mixture in a 2% agarose gel containing 0.5Wg/ml ethidium bromide.
3. Results
AGEs have been shown to activate the transcription factor
NF-UB and to upregulate various NF-UB-controlled genes in
various cell types [7,26]. This can be seen in the clonal mouse
macrophages line J774 too, where addition of BSA-AGE ac-
tivates NF-UB, as demonstrated by the translocation of NF-
UB subunits into the nucleus. Binding of the NF-UB subunits
Fig. 1. Chemical reactions leading to the formation of advanced glycation endproducts.
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to the labeled oligonucleotide containing the NF-UB consen-
sus sequence was speci¢c, as it could be inhibited by the ad-
dition of excess unlabeled oligonucleotide (Fig. 2, lanes 4^6).
The activated NF-UB complex contains p50, as demonstrated
by a supershift assay with an anti-p50 antibody (Fig. 2, lane
1). The 2w-BSA-AGE was less e¡ective in activating NF-UB
than BSA-AGE (Fig. 2, lanes 2, 3).
BSA-AGE leads to a strongly active NF-UB complex after
6 h of incubation, whereas 15 min preincubation of cells with
HMW-HA (MW: 1.2U106 Da) at a concentration of 4 mg/ml
completely inhibited the BSA-AGE-induced activation of NF-
UB (Fig. 3, lanes 2, 3). One of the major cell surface receptors
for hyaluronic acid is CD44, therefore an anti-CD44 antibody
was used to inhibit the binding of HA to the macrophage
CD44 receptors. This restored the BSA-AGE-induced trans-
location of the activated NF-UB complex into the nucleus
(Fig. 3, lane 5), with a somewhat di¡erent pattern of the
activated NF-UB complex. The anti-CD44 antibody, HMW-
HA and BSA showed no NF-UB-activating e¡ects (Fig. 3
lanes 6, 4 and 1).
The protective e¡ect of the HA diminished with decreasing
molecular weight of HA from 1.2 MDa to 0.3^0.5 MDa (Fig.
4A). At a size below 0.5 MDa the HA not only lost its pro-
tective e¡ect, it became NF-UB-activating itself. This was only
slightly reduced by the anti-CD44 antibody (Fig. 4B, lanes 3,
4). The activating e¡ect seemed to be equivalent to that of the
BSA-AGE, whereas the two activators did not act synergisti-
cally (Fig. 4B, lanes 1, 2). Other glycosaminoglycans like D-
glucuronic acid, N-acetylglucosamine and chondroitin sulfate
were not able to protect the macrophages from BSA-AGE-
induced NF-UB activation (Fig. 4B, lanes 6^8), as the result-
ing NF-UB complex was nearly as prominent as that of BSA-
AGE (lane 5). These three glycosaminoglycans did not acti-
vate NF-UB (data not shown), an e¡ect already described for
the cell line RAW 264.7 [27].
HMW-HA interference with NF-UB-mediated signaling in-
duced by AGEs was investigated further downstream by ana-
lyzing the expression of the NF-UB-regulated pro-in£amma-
Fig. 2. Addition of 2 WM BSA-AGE (lane 3) leads to a strong acti-
vation of NF-UB in J774 macrophages, with 2w-BSA-AGE the acti-
vation was lower (lane 2). The binding of the NF-UB complexes to
the radiolabeled NF-UB probe was inhibited by 1-, 3- and 7-fold ex-
cess of non-radioactive oligonucleotide (lanes 4, 5, 6). Addition of
p50 antibody supershifted the NF-UB complex (lane 1).
Fig. 3. J774 macrophages exhibited an activation of NF-UB after 6 h
by BSA-AGE (lane 2), a process attenuated by HMW-HA (lane 3).
This protective e¡ect was abolished by anti-CD44 antibodies (lane
5). BSA, HMW-HA or anti-CD44 antibody had no e¡ect on the
translocation of NF-UB (lanes 1, 4 and 6).
Fig. 4. A: The protective e¡ect of the HA decreased with shrinking
size from 1.2 MDa via 0.7 MDa, 0.6 MDa down to 0.3^0.5 MDa.
B: LMW-HA activated NF-UB to a similar extent as BSA-AGE
(lanes 3, 1) but showed no synergistic e¡ects together with BSA-
AGE (lane 2). The anti-CD44 antibody reduced the active NF-UB
complex (lane 4) in parts. The glycosaminoglycans D-glucuronic-
acid, N-acetylglucosamine and chondroitin sulfate (lanes 6, 7 and 8)
were not able to inhibit BSA-AGE-activated NF-UB, so that the
NF-UB activation was comparable to that of BSA-AGE (lane 5).
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tory cytokines IL-1K, IL-6 and TNF-K at the mRNA level.
Addition of HMW-HA inhibited the AGE-induced increase in
expression of IL-1K, IL-6 and TNF-K after 24 h as detected
by RT-PCR, consistent with its e¡ects on NF-UB (Fig. 5).
4. Discussion
Glucose has been implicated in the ageing process by its
ability to react non-enzymatically with long-lived proteins to
produce AGEs, which increase in tissues as a function of time
(e.g. with age) and sugar concentration [28]. AGEs induce
permanent abnormalities in extracellular matrix component
function, stimulate cytokine and reactive oxygen species pro-
duction through AGE-speci¢c receptors, and modify intracel-
lular proteins. AGEs are thus suggested to be promoters of
chronic in£ammation and to cause an imbalance of prolifer-
ation and degeneration as described for diabetic retinopathy,
nephropathy, neuropathy, arterial abnormalities, as well as in
Alzheimer’s disease and rheumatoid arthritis.
No extracellular physiological counterparts (‘AGE antago-
nists’) able to attenuate AGE-induced pro-in£ammatory sig-
nal transduction have been described to date. Our results
show that HMW-HA with a molecular weight above 1.2
MDa is an inhibitor of AGE-induced signal transduction,
whereas with decreasing size of HA this inhibition is gradually
reduced. In addition to their diminished protection smaller
HA fragments (6 0.5 MDa) are pro-in£ammatory. This de-
pendence of the pro-in£ammatory e¡ects of HA on its molec-
ular weight might also explain the con£icting reports in the
literature concerning the anti-in£ammatory potential of HA.
Recently other reports regarding the opposing e¡ects of
LMW-HA and HMW-HA have appeared in the literature.
For example, small HA fragments (MW: 3.5U104 Da), but
not physiological native HA polymers (MW: 2.2U106), were
shown to induce prostanoid production via increased COX-2
expression [29]. In mouse cortical tubular (MCT) cells frag-
mented intermediate HA, but not HMW-HA markedly in-
creased ICAM-1 and VCAM-1 expression. Upregulation of
ICAM-1 and VCAM-1 by LMW-HA was preceded by a
marked increase in NF-UB and AP-1 activation [23]. These
data also explain the bene¢cial e¡ects of injections of syn-
thetic HMW-HA preparations on chronic in£ammatory con-
ditions in joints, such as the knee and the mandible [30].
Although our results indicate that the protective e¡ect of
HMW-HA could be mediated through CD44, it remains to
be elucidated whether CD44 signal transduction pathways,
such as the src family protein tyrosine kinases lck and fyn,
interfere with AGE signal transduction [31] or whether
HMW-HA inhibits AGE/RAGE binding by steric e¡ects.
There are two possible physiological causes for the decrease
of the molecular weight of HA in vivo: aging and radical-
induced depolymerization. The average size of the HA po-
lymers decreases with age, as measured in human cartilage
(where the molecular weight drops from s 2 MDa in new-
borns to about 0.3 MDa at the age of 80) and in aqueous
humor and vitreous body of rabbit and cattle [32,33]. The age-
related decrease in HA size might also be a reason for the
increased susceptibility of the elderly to (AGE-induced)
chronic in£ammations. High radical burden, e.g. at sites of
in£ammation, also leads to a degradation of HA by released
oxidants such as O32 /H2O2/HO
 and HOCl/ClO3 [34]. These
data also explain the observed high levels of HA at sites of
in£ammation, which are most probably LMW-HA fragments
released by radical-induced depolymerization.
Since the molecular weight of HA decreases with age and in
regions of high radical load, we suggest that HA loses its
protective properties under these conditions leading to a vi-
cious circle of chronic in£ammation, oxidative stress and rad-
ical-induced HA depolymerization.
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